Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06291987 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Name: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — clinical trial record (NCT06291987)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MPN

StatusRecruiting

PhasePhase 1

SponsorUniversity of Chicago

Started2024-09-19

View on ClinicalTrials.gov ↗

The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs.

Amendment history 2 changes detected by DataLookout

2026-09-02

Primary completion pushed: 2026-05 → 2029-05

2026-09-02

Completion pushed: 2026-05 → 2029-05

Trial Details

NCT Number	NCT06291987
Lead Sponsor	University of Chicago
Conditions	Myeloproliferative Neoplasms
Enrollment	18 participants
Start Date	2024-09-19
Primary Completion	2029-05 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-09-01